Tedros Adhanom Ghebreyesus & Gilead Sciences

Tedros Adhanom Ghebreyesus: Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, announced the launch of the trial and provided updates on the Ebola outbreak, highlighting the urgency and hope associated with the study.

Gilead Sciences: Gilead Sciences is the developer of remdesivir, one of the antiviral drugs being evaluated in the clinical trial for Ebola. The company has donated doses of the drug for the study.

Tedros Adhanom Ghebreyesus: Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, declared the Bundibugyo ebolavirus outbreak a Public Health Emergency of International Concern and welcomed the development of the new diagnostic test, emphasizing its importance in strengthening outbreak control.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir is being evaluated in combination with Mapp Biopharmaceutical's MBP134 antibody in a treatment trial for the Bundibugyo Ebola outbreak.